Mr. Del Col holds a Bachelor of Science degree in Pharmacy from the University of Toronto and a Master’s in Business Administration from the York University Schulich School of Business. Throughout his extensive professional career, Mr. Del Col has gained knowledge and experience not only as a community pharmacist, but also as a financial analyst for a multinational pharmaceutical company and as National Director of Sales and Marketing for a leading health and beauty products corporation. Since being diagnosed with multiple myeloma in 2002, Mr. Del Col has directed his attention to building an effective national platform to address the needs of the Canadian myeloma community. Co-founded by Mr. Del Col in 2005, Myeloma Canada is the only national non-profit organization uniquely focused on the needs of this community.
Over the past ten years, Aldo Del Col has worked steadily to build a strong foundation and firmly establish Myeloma Canada’s position as an effective national platform for the Canadian myeloma community, first as a volunteer and President of the Board of Directors, and since 2010 as Executive Director. In this capacity, Mr. Del Col’s leadership responsibilities included the implementation of board policy, development of programs and services, advancement of community relations with a broad range of stakeholders, and oversight of the organization’s financial management. With the hiring of a new Executive Director in April 2013, Mr. Del Col has focused his attention on advancing myeloma research in Canada. In his new role as Chief Scientific Advisor, Mr. Del Col will draw on his scientific and pharmaceutical background to work closely with the Myeloma Canada Research Network (MCRN) to drive research focused on optimizing patient outcomes. An important first step in the evolution of the MCRN into a leading international clinical trials research group was the activation of its first clinical trial, MCRN 001, early in 2013.
In addition to his ongoing responsibilities with Myeloma Canada, Mr. Del Col is a licensed pharmacist, is co-leader of the Myeloma Montreal Support Network, which he founded in 2005, and serves as the patient representative for hematology in the Clinical Trials Group of the National Cancer Institute of Canada (NCIC). Aldo is also a member of the Global Myeloma Alliance Steering Committee, is actively involved with the Canadian Organization for Rare Disorders (CORD), and is a volunteer for Hope and Cope, a cancer patient support organization at the Jewish General Hospital in Montreal, where he is being treated.
Johanne Mullen is a partner in the Deals Practice of PricewaterhouseCoopers LLP working in the Montreal office. She specializes in project financing and public-private partnerships.
Johanne provides advice to public and private sector clients with respect to the development and financing of large projects, notably in the infrastructure sector. Her advisory experience includes developing business cases, developing financing and funding strategies, securing credit ratings, running competitions to identify financiers, as well as implementing, negotiating and closing financings.
Johanne has had a particular focus on large or complex projects with multiple stakeholders. She is also an expert in the analysis and implementation of public private partnerships, including the development of initial business cases, procurement processes and proposal evaluations. She has worked both with the public sector (provincial, federal and municipal governments) and with the private sector in the successful conclusion of large complex projects.
Recent mandates include:
Johanne holds a Bachelor of Commerce in Finance from Concordia University and a Master of Business Administration in International Business from McGill University.
Ellis Basevitz, a founder of the accounting firm PSB Boisjoli more than 45 years ago, owes his success to his ability to establish lasting relationships with clients and business partners. Known for his passion and enthusiasm for problem solving, he provides original and creative ideas that help clients save money and grow their assets. His services are based on mutual trust, knowing how to listen to and understand the needs and objectives of his clients, and becoming their partner in the development of short and long-term strategies, whether personal or business.
During his career, Ellis has been a mentor and an example for many young accountants who have now become partners. He has transmitted to them his philosophy on customer service and trained them to provide value-added services.
Within the firm, Ellis is a consultant valued for his vision, creativity and originality, and has assumed marketing and business development roles.
Academic credentials, professional accreditation and associations
Dr. Reece is Professor of Medicine at University of Toronto and Director of the Program for Multiple Myeloma and Related Diseases in the Department of Medical Oncology and Hematology at Princess Margaret Hospital/University of Toronto. Dr. Reece holds the Molly & David Bloom Chair in Multiple Myeloma Research and is chair of the Multiple Myeloma Clinical Trials Group of the National Cancer Institute of Canada, as well as a co-chair of the Myeloma Working Committee at the Center for International Blood and Marrow Transplant Research. She also serves on the Myeloma Canada Scientific Advisory Board and leads the Myeloma Canada Research Network.
Eric has been involved in the field of myeloma for more than 15 years. Working as a volunteer in the United States for the International Myeloma Foundation, he recognised the need and the benefit of providing information and support to people affected by myeloma. Returning to the United Kingdom, Eric identified the need for a similar organisation in that country and as a result, he set up Myeloma UK in 1997.
Under Eric’s direction, Myeloma UK has grown and developed and is the only UK cancer organisation dealing exclusively with myeloma. The organisation currently employs 34 staff members and provides a broad range of services covering every aspect of myeloma, from information and support to improving standards of treatment and care through research, education, information, support, campaigning and raising awareness. Today, Myeloma UK reaches more than 12,000 people affected by myeloma, along with the majority of healthcare professionals involved in their care.
As Chief Executive, Eric has been instrumental in developing the organisation’s ‘bench-to-bedside’ strategy, an integrated model to systematically address and remove the barriers that prevent or delay research, development and access to new treatments, as well as optimal treatment, care, information and support.
Among a very busy portfolio of projects, Eric’s recent achievements have included establishing the national Myeloma Early Phase Clinical Trial Network and a myeloma genetics and drug development research program. Eric has also ensured that myeloma patients in the UK can access novel treatments through advocating solution-oriented approaches to the way drugs are made available through the NHS.
Eric currently has a particular interest in drug pricing and in developing innovative ways to translate the outcomes of clinical research into clinical practice. He is also currently working on a number of initiatives, including the development of an outcomes registry, state-of-the-art treatment pathways and guidelines, and a myeloma bio-banking strategy. He is an active member of a number of myeloma and cancer-related boards, steering groups and committees.
Eric spends much of his time out and about, meeting with representatives from the myeloma community and tirelessly campaigning on behalf of myeloma patients for the very best standards of treatment and care. Through his passion and enthusiasm, he has significantly raised the profile of myeloma in the medical, political and media communities.
At the Queen’s Birthday Honours in 2012, Eric was awarded an OBE for his services to charity as Chief Executive of Myeloma UK.
A native of Winnipeg, Manitoba, Cindy graduated with a Bachelor of Nursing degree from the University of Manitoba in 2001. After working for six months at the Women’s Hospital of the Health Sciences Centre in Winnipeg,, Cindy moved to Vancouver, B.C. and began working on the Leukemia/BMT ward. After working on the ward for three years, she transferred to the medical daycare unit, where patients receive post-transplant or post-chemotherapy care. After one year in the medical daycare unit, Cindy became a clinical research nurse – her “dream job” – and has remained in this position for the past nine years.
Over this time, Cindy has developed a passion for multiple myeloma and has acquired a deep understanding of the disease. She has been involved in numerous nursing advisory programs, where she has educated other nurses from across Canada on multiple myeloma and symptom management, as well as helped develop tools for use in supportive care. She has also presented these programs to nurses and pharmacists across Canada who treat multiple myeloma patients. This year, she is pursuing her Master’s of Science in Nursing at UBC and will focus on research in myeloma patients.
Cindy’s wish is to have a cure for multiple myeloma, but in the meantime, she strives to ensure that all myeloma patients receive the best quality of life possible, which can only be achieved with the collaboration and education of healthcare staff, patients, caregivers and researchers.
Myeloma Canada is affiliated with the International Myeloma Foundation, the world's oldest and largest myeloma organization
Myeloma Canada gratefully acknowledges the generous unrestricted educational grants from our website sponsors: